Month: September 2020

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today announced that the Company will participate in Barclays CEO Energy-Power Conference that will be held virtually this year on September 8-10.Chairman and Chief Executive Officer Tracy W. Krohn is scheduled to make a presentation on Thursday morning, September 10 at 9:45 am eastern time and will also host virtual one-on-one meetings that day.  The presentation will be webcast live and archived on W&T’s website, www.wtoffshore.com, in the Investor Relations section of the site, on the “News and Events” page.  An updated investor slide deck prepared in conjunction with the Barclays Conference will be posted in the Investor Relations section of W&T’s website on Thursday morning, September 10, prior to the presentation.About...

BEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of application development and digital experience technologies, today announced preliminary financial results for its fiscal third quarter ended August 31, 2020 and business outlook for the full year of 2020.Fiscal Third Quarter 2020 Preliminary ResultsProgress’ normal financial closing and financial statement preparation processes are in their preliminary stages.  However, using the most current information available to management, Progress expects its fiscal third quarter 2020 financial results to be within the following ranges:Progress’ preliminary financial results for the fiscal third quarter 2020 reflect better than expected revenue performance across certain of our product lines coupled with a continued focus on cost management...

Jean-François Lequoy est nommé directeur général du Groupe BPCE, en charge des finances et de la stratégie, membre du directoire  Paris, le 7 septembre 2020Le conseil de surveillance du Groupe BPCE a approuvé ce jour la nomination de Jean-François Lequoy actuel directeur général de Natixis Assurances, en tant que membre du directoire du Groupe BPCE, en charge des finances et de la stratégie.Il prendra ses fonctions le 14 septembre et succède à Nicolas Namias, nommé directeur général de Natixis le 3 août.Jean-François Lequoy a rejoint Natixis en 2014 pour réaliser le projet de constitution du pôle assurances visant à faire du Groupe BPCE un bancassureur de plein exercice. Chez Natixis Assurances, il a ainsi créé avec succès un groupe d’assurance intégré et performant au service des Banques Populaires et des Caisses d’Epargne, tant en assurance...

Jean-François Lequoy est nommé directeur général du Groupe BPCE, en charge des finances et de la stratégie, membre du directoire  Paris, le 7 septembre 2020Le conseil de surveillance du Groupe BPCE a approuvé ce jour la nomination de Jean-François Lequoy actuel directeur général de Natixis Assurances, en tant que membre du directoire du Groupe BPCE, en charge des finances et de la stratégie.Il prendra ses fonctions le 14 septembre et succède à Nicolas Namias, nommé directeur général de Natixis le 3 août.Jean-François Lequoy a rejoint Natixis en 2014 pour réaliser le projet de constitution du pôle assurances visant à faire du Groupe BPCE un bancassureur de plein exercice. Chez Natixis Assurances, il a ainsi créé avec succès un groupe d’assurance intégré et performant au service des Banques Populaires et des Caisses d’Epargne, tant en assurance...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) is pleased to report that initial drilling on the new ground acquired through its recent acquisition of Balmoral Resources Ltd. (“Balmoral”) has greatly expanded the ultimate size potential of the Fenelon Gold System.Recent drilling has extended gold mineralization 500 metres to the west and 850 metres to the south of Area 51. This greatly expands the ultimate potential size of the Area 51 vein network gold mineralization on Wallbridge’s 100%-owned Fenelon Gold Property (“Fenelon” or the “Property”). The Area 51 vein network, along with the Tabasco, Cayenne and Gabbro Zones, form parts of a large gold system (“Fenelon Gold System”) located within and adjacent to the Jeremie Diorite, which has now been traced for...

Acquisition aligns with strategy for accretive acquisition and extends product offerings in DevOps and DevSecOps with market-leading infrastructure automationBEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of application development and digital experience technologies, today announced that it has entered into a definitive agreement to acquire Chef, a global leader in DevOps and DevSecOps, providing complete infrastructure automation to build, deploy, manage and secure applications in modern multi-cloud and hybrid environments, as well as on-premises.    “Chef is a market leader with best-in-class products, a vibrant developer community, an impressive blue-chip customer base and highly skilled and engaged employees,” said Yogesh Gupta, CEO, Progress. “Chef has built a successful business,...

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the U.S. Food and Drug Administration (“FDA” or “the Agency”) has granted approval for the company to proceed with a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States. “This is a key milestone in the history of our company as it helps pave the way for us to initiate a clinical trial of CGuard EPS for addressing Carotid Artery Disease and preventing stroke in the United States market. This will be the first U.S.-based study of CGuard which is a cornerstone of our global expansion plans,” said Marvin Slosman, InspireMD’s CEO. “A...

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a Loss of Cortisol Response in 54.5 Percent (p=0.0002) More Patients than the RECORLEV® (levoketoconazole) Arm ~~ RECORLEV® (levoketoconazole) was Generally Well Tolerated with a Safety and Tolerability Profile Comparable to the Profile Observed in the Phase 3 SONICS Study ~~ Company Anticipates Submitting a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021; If Approved, Expects to Launch RECORLEV in the First Quarter of 2022 ~~ Company to Host Conference Call Today at 8:30 a.m. ET ~DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:...

VANCOUVER, British Columbia, Sept. 08, 2020 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG Silver”) is pleased to announce that the US$50 million at-the-market equity program (the “ATM Program”) previously announced (see Press Release June 30, 2020) has been completed.  Since June 30, 2020, MAG Silver sold and issued 3,092,783 common shares under the ATM Program at an average price of US$16.16 per share, for gross and net proceeds of US$50 million and US$48.625 million, respectively. There is no further remaining availability under this ATM Program.Under the ATM Program, MAG Silver was permitted to issue up to an aggregate of US$50 million worth of common shares from treasury, at prevailing market prices to the public through the NYSE American or any other marketplace on which the common shares are listed,...

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccinesNEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech SE (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.All nine CEOs signed the following pledge:We, the undersigned biopharmaceutical companies,...